###begin article-title 0
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 37 42 <span type="species:ncbi:9606">human</span>
Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 230 238 226 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 515 523 511 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 645 653 641 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 769 777 765 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
Insulin secretion in pancreatic islets is dependent upon mitochondrial function and production of ATP. The transcriptional coactivator peroxisome proliferator activated receptor gamma coactivator-1 alpha (protein PGC-1alpha; gene PPARGC1A) is a master regulator of mitochondrial genes and its expression is decreased and related to impaired oxidative phosphorylation in muscle from patients with type 2 diabetes. Whether it plays a similar role in human pancreatic islets is not known. We therefore investigated if PPARGC1A expression is altered in islets from patients with type 2 diabetes and whether this expression is influenced by genetic (PPARGC1A Gly482Ser polymorphism) and epigenetic (DNA methylation) factors. We also tested if experimental downregulation of PPARGC1A expression in human islets influenced insulin secretion.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 155 163 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 204 212 204 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 350 358 350 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 315 320 <span type="species:ncbi:9606">human</span>
The PPARGC1A Gly482Ser polymorphism was genotyped in human pancreatic islets from 48 non-diabetic and 12 type 2 diabetic multi-organ donors and related to PPARGC1A mRNA expression. DNA methylation of the PPARGC1A promoter was analysed in pancreatic islets from ten type 2 diabetic and nine control donors. Isolated human islets were transfected with PPARGC1A silencing RNA (siRNA).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 181 189 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 311 319 309 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 395 403 393 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 455 463 453 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 481 482 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 525 526 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 579 587 577 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 701 702 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
PPARGC1A mRNA expression was reduced by 90% (p < 0.005) and correlated with the reduction in insulin secretion in islets from patients with type 2 diabetes. After downregulation of PPARGC1A expression in human islets by siRNA, insulin secretion was reduced by 41% (p </= 0. 01). We were able to ascribe reduced PPARGC1A expression in islets to both genetic and epigenetic factors, i.e. a common PPARGC1A Gly482Ser polymorphism was associated with reduced PPARGC1A mRNA expression (p < 0.00005) and reduced insulin secretion (p < 0.05). In support of an epigenetic influence, the PPARGC1A gene promoter showed a twofold increase in DNA methylation in diabetic islets compared with non-diabetic islets (p < 0.04).
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
We have shown for the first time that PPARGC1A might be important in human islet insulin secretion and that expression of PPARGC1A in human islets can be regulated by both genetic and epigenetic factors.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 578 586 574 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 756 757 752 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 808 816 804 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 940 941 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 998 1006 994 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1110 1118 1106 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1131 1132 1127 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1133 1134 1129 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1175 1183 1171 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1240 1241 1236 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1394 1395 1386 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 1329 1334 <span type="species:ncbi:9606">human</span>
Type 2 diabetes is characterised by chronic hyperglycaemia as a result of impaired pancreatic beta cell function and insulin resistance in peripheral tissues, i.e. skeletal muscle, adipose tissue and liver. Although each of these pathogenic defects could be accounted for by specific mechanisms, impaired ATP production as a consequence of reduced oxidative phosphorylation might provide an intriguing common pathogenic pathway for all these defects. The transcriptional coactivator peroxisome proliferator activated receptor gamma coactivator-1 alpha (protein PGC-1alpha; gene PPARGC1A) is an important factor regulating the expression of genes for oxidative phosphorylation and ATP production in target tissues through coactivation of nuclear receptors [1]. We have previously shown that the expression of PPARGC1A and a set of genes involved in oxidative phosphorylation is reduced in skeletal muscle from patients with type 2 diabetes [2]. Furthermore, a common polymorphism, Gly482Ser, in the PPARGC1A gene has been associated with increased risk of type 2 diabetes and an age-related reduction in muscle PPARGC1A expression [3-5]. In addition, genetic variation in the PPARGC1A gene was associated with indices of beta cell function [6]. Despite the central role of ATP for insulin secretion, the function of PGC-1alpha in human pancreatic islets and beta cells is less well established [7].
###end p 11
###begin p 12
Obesity, reduced physical activity and ageing are well known risk factors for type 2 diabetes. However, all individuals exposed to an affluent environment do not develop the disease. One likely reason is that genetic variation modifies individual susceptibility to the environment. However, the environment could also modify genetic risk factors by influencing expression of a gene by DNA methylation or histone modifications. Cytosine residues occurring in CG dinucleotides are targets for DNA methylation and gene expression is usually reduced when DNA methylation takes place at a promoter. Whether DNA methylation influences gene expression in target tissues for type 2 diabetes and thereby the pathogenesis of the disease remains to be demonstrated.
###end p 12
###begin p 13
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 283 291 283 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
The present study investigated: (1) whether expression of PPARGC1A is altered in human islets from patients with type 2 diabetes; (2) if this expression is influenced by genetic (the PPARGC1A Gly482Ser polymorphism) and epigenetic (DNA methylation) factors; and (3) if expression of PPARGC1A influences insulin secretion.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Multi-organ donors</bold>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 277 284 277 284 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 284 351 284 351 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">Clinical characteristics of type 2 diabetic and non-diabetic donors</p>
###xml 284 351 284 351 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">Clinical characteristics of type 2 diabetic and non-diabetic donors</p></caption>
###xml 351 352 351 352 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 352 371 352 371 <th xmlns:xlink="http://www.w3.org/1999/xlink">Non-diabetic donors</th>
###xml 371 393 371 393 <th xmlns:xlink="http://www.w3.org/1999/xlink">Type 2 diabetic donors</th>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 393 400 393 400 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 351 400 351 400 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th>Non-diabetic donors</th><th>Type 2 diabetic donors</th><th><italic>p</italic> value</th></tr>
###xml 351 400 351 400 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th>Non-diabetic donors</th><th>Type 2 diabetic donors</th><th><italic>p</italic> value</th></tr></thead>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 400 415 400 415 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>n</italic> (male/female)</td>
###xml 415 425 415 425 <td xmlns:xlink="http://www.w3.org/1999/xlink">48 (30/18)</td>
###xml 425 433 425 433 <td xmlns:xlink="http://www.w3.org/1999/xlink">12 (6/6)</td>
###xml 433 434 433 434 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 400 434 400 434 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2"><italic>n</italic> (male/female)</td><td>48 (30/18)</td><td>12 (6/6)</td><td>&#160;</td></tr>
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 434 442 434 442 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (7/2)<sup>a</sup></td>
###xml 450 451 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 442 451 442 451 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (5/5)<sup>a</sup></td>
###xml 451 452 451 452 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 434 452 434 452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>9 (7/2)<sup>a</sup></td><td>10 (5/5)<sup>a</sup></td><td>&#160;</td></tr>
###xml 452 463 452 463 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Age (years)</td>
###xml 463 475 463 473 <td xmlns:xlink="http://www.w3.org/1999/xlink">53.2&#8201;&#177;&#8201;2.4</td>
###xml 475 487 473 483 <td xmlns:xlink="http://www.w3.org/1999/xlink">66.7&#8201;&#177;&#8201;2.4</td>
###xml 487 492 483 488 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.05</td>
###xml 452 492 452 488 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">Age (years)</td><td>53.2&#8201;&#177;&#8201;2.4</td><td>66.7&#8201;&#177;&#8201;2.4</td><td rowspan="2">&lt;0.05</td></tr>
###xml 504 505 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 492 505 488 499 <td xmlns:xlink="http://www.w3.org/1999/xlink">54.2&#8201;&#177;&#8201;3.5<sup>a</sup></td>
###xml 517 518 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 505 518 499 510 <td xmlns:xlink="http://www.w3.org/1999/xlink">65.1&#8201;&#177;&#8201;2.6<sup>a</sup></td>
###xml 492 518 488 510 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>54.2&#8201;&#177;&#8201;3.5<sup>a</sup></td><td>65.1&#8201;&#177;&#8201;2.6<sup>a</sup></td></tr>
###xml 527 528 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 518 529 510 521 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">BMI (kg/m<sup>2</sup>)</td>
###xml 529 541 521 531 <td xmlns:xlink="http://www.w3.org/1999/xlink">24.8&#8201;&#177;&#8201;0.6</td>
###xml 541 553 531 541 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.1&#8201;&#177;&#8201;1.0</td>
###xml 553 558 541 546 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.05</td>
###xml 518 558 510 546 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">BMI (kg/m<sup>2</sup>)</td><td>24.8&#8201;&#177;&#8201;0.6</td><td>27.1&#8201;&#177;&#8201;1.0</td><td rowspan="2">&lt;0.05</td></tr>
###xml 570 571 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 558 571 546 557 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.9&#8201;&#177;&#8201;1.3<sup>a</sup></td>
###xml 583 584 567 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 571 584 557 568 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.9&#8201;&#177;&#8201;1.1<sup>a</sup></td>
###xml 558 584 546 568 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>25.9&#8201;&#177;&#8201;1.3<sup>a</sup></td><td>26.9&#8201;&#177;&#8201;1.1<sup>a</sup></td></tr>
###xml 595 596 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 584 596 568 580 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gly/Gly (%)<sup>b</sup></td>
###xml 596 600 580 584 <td xmlns:xlink="http://www.w3.org/1999/xlink">53.3</td>
###xml 600 604 584 588 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.3</td>
###xml 604 605 588 589 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 584 605 568 589 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gly/Gly (%)<sup>b</sup></td><td>53.3</td><td>27.3</td><td>&#160;</td></tr>
###xml 624 625 608 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 605 625 589 609 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gly/Ser+Ser/Ser (%)<sup>b</sup></td>
###xml 625 629 609 613 <td xmlns:xlink="http://www.w3.org/1999/xlink">46.7</td>
###xml 629 633 613 617 <td xmlns:xlink="http://www.w3.org/1999/xlink">72.3</td>
###xml 633 634 617 618 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 605 634 589 618 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gly/Ser+Ser/Ser (%)<sup>b</sup></td><td>46.7</td><td>72.3</td><td>&#160;</td></tr>
###xml 400 634 400 618 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="2"><italic>n</italic> (male/female)</td><td>48 (30/18)</td><td>12 (6/6)</td><td>&#160;</td></tr><tr><td>9 (7/2)<sup>a</sup></td><td>10 (5/5)<sup>a</sup></td><td>&#160;</td></tr><tr><td rowspan="2">Age (years)</td><td>53.2&#8201;&#177;&#8201;2.4</td><td>66.7&#8201;&#177;&#8201;2.4</td><td rowspan="2">&lt;0.05</td></tr><tr><td>54.2&#8201;&#177;&#8201;3.5<sup>a</sup></td><td>65.1&#8201;&#177;&#8201;2.6<sup>a</sup></td></tr><tr><td rowspan="2">BMI (kg/m<sup>2</sup>)</td><td>24.8&#8201;&#177;&#8201;0.6</td><td>27.1&#8201;&#177;&#8201;1.0</td><td rowspan="2">&lt;0.05</td></tr><tr><td>25.9&#8201;&#177;&#8201;1.3<sup>a</sup></td><td>26.9&#8201;&#177;&#8201;1.1<sup>a</sup></td></tr><tr><td>Gly/Gly (%)<sup>b</sup></td><td>53.3</td><td>27.3</td><td>&#160;</td></tr><tr><td>Gly/Ser+Ser/Ser (%)<sup>b</sup></td><td>46.7</td><td>72.3</td><td>&#160;</td></tr></tbody>
###xml 351 634 351 618 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Non-diabetic donors</th><th>Type 2 diabetic donors</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td rowspan="2"><italic>n</italic> (male/female)</td><td>48 (30/18)</td><td>12 (6/6)</td><td>&#160;</td></tr><tr><td>9 (7/2)<sup>a</sup></td><td>10 (5/5)<sup>a</sup></td><td>&#160;</td></tr><tr><td rowspan="2">Age (years)</td><td>53.2&#8201;&#177;&#8201;2.4</td><td>66.7&#8201;&#177;&#8201;2.4</td><td rowspan="2">&lt;0.05</td></tr><tr><td>54.2&#8201;&#177;&#8201;3.5<sup>a</sup></td><td>65.1&#8201;&#177;&#8201;2.6<sup>a</sup></td></tr><tr><td rowspan="2">BMI (kg/m<sup>2</sup>)</td><td>24.8&#8201;&#177;&#8201;0.6</td><td>27.1&#8201;&#177;&#8201;1.0</td><td rowspan="2">&lt;0.05</td></tr><tr><td>25.9&#8201;&#177;&#8201;1.3<sup>a</sup></td><td>26.9&#8201;&#177;&#8201;1.1<sup>a</sup></td></tr><tr><td>Gly/Gly (%)<sup>b</sup></td><td>53.3</td><td>27.3</td><td>&#160;</td></tr><tr><td>Gly/Ser+Ser/Ser (%)<sup>b</sup></td><td>46.7</td><td>72.3</td><td>&#160;</td></tr></tbody></table>
###xml 634 668 618 650 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Data are expressed as mean&#8201;&#177;&#8201;SEM</p>
###xml 668 669 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 668 709 650 691 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><sup>a</sup>Donors used for DNA methylation analysis</p>
###xml 709 710 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 710 718 692 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 709 741 691 723 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19"><sup>b</sup><italic>PPARGC1A</italic> Gly482Ser polymorphism</p>
###xml 634 741 618 723 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Data are expressed as mean&#8201;&#177;&#8201;SEM</p><p textid="18"><sup>a</sup>Donors used for DNA methylation analysis</p><p textid="19"><sup>b</sup><italic>PPARGC1A</italic> Gly482Ser polymorphism</p></table-wrap-foot>
###xml 277 741 277 723 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="16">Clinical characteristics of type 2 diabetic and non-diabetic donors</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Non-diabetic donors</th><th>Type 2 diabetic donors</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td rowspan="2"><italic>n</italic> (male/female)</td><td>48 (30/18)</td><td>12 (6/6)</td><td>&#160;</td></tr><tr><td>9 (7/2)<sup>a</sup></td><td>10 (5/5)<sup>a</sup></td><td>&#160;</td></tr><tr><td rowspan="2">Age (years)</td><td>53.2&#8201;&#177;&#8201;2.4</td><td>66.7&#8201;&#177;&#8201;2.4</td><td rowspan="2">&lt;0.05</td></tr><tr><td>54.2&#8201;&#177;&#8201;3.5<sup>a</sup></td><td>65.1&#8201;&#177;&#8201;2.6<sup>a</sup></td></tr><tr><td rowspan="2">BMI (kg/m<sup>2</sup>)</td><td>24.8&#8201;&#177;&#8201;0.6</td><td>27.1&#8201;&#177;&#8201;1.0</td><td rowspan="2">&lt;0.05</td></tr><tr><td>25.9&#8201;&#177;&#8201;1.3<sup>a</sup></td><td>26.9&#8201;&#177;&#8201;1.1<sup>a</sup></td></tr><tr><td>Gly/Gly (%)<sup>b</sup></td><td>53.3</td><td>27.3</td><td>&#160;</td></tr><tr><td>Gly/Ser+Ser/Ser (%)<sup>b</sup></td><td>46.7</td><td>72.3</td><td>&#160;</td></tr></tbody></table><table-wrap-foot><p textid="17">Data are expressed as mean&#8201;&#177;&#8201;SEM</p><p textid="18"><sup>a</sup>Donors used for DNA methylation analysis</p><p textid="19"><sup>b</sup><italic>PPARGC1A</italic> Gly482Ser polymorphism</p></table-wrap-foot></table-wrap>
Multi-organ donors The characteristics of the 48 non-diabetic and 12 type 2 diabetic multi-organ donors, whose pancreases were processed for islet preparation, are presented in Table 1. Pancreases were obtained and processed with the approval of the regional Ethics Committee. Table 1Clinical characteristics of type 2 diabetic and non-diabetic donors Non-diabetic donorsType 2 diabetic donorsp valuen (male/female)48 (30/18)12 (6/6) 9 (7/2)a10 (5/5)a Age (years)53.2 +/- 2.466.7 +/- 2.4<0.0554.2 +/- 3.5a65.1 +/- 2.6aBMI (kg/m2)24.8 +/- 0.627.1 +/- 1.0<0.0525.9 +/- 1.3a26.9 +/- 1.1aGly/Gly (%)b53.327.3 Gly/Ser+Ser/Ser (%)b46.772.3 Data are expressed as mean +/- SEMaDonors used for DNA methylation analysisbPPARGC1A Gly482Ser polymorphism
###end p 15
###begin p 16
Clinical characteristics of type 2 diabetic and non-diabetic donors
###end p 16
###begin p 17
Data are expressed as mean +/- SEM
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aDonors used for DNA methylation analysis
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 9 1 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
bPPARGC1A Gly482Ser polymorphism
###end p 19
###begin p 20
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human pancreatic islets and experimental plan</bold>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human pancreatic islets and experimental plan Isolated pancreatic islets were prepared by collagenase digestion and density gradient purification [8, 9]. After isolation, islets were cultured free floating in M199 culture medium (Sigma-Aldrich, St Louis, MO, USA) at 5.5 mmol/l glucose concentration and studied within 3 days from isolation. Cell viability, measured by Trypan Blue exclusion, was higher than 90% in control and diabetic islets after 3 days in culture.
###end p 20
###begin p 21
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Insulin secretion study</bold>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Insulin secretion study Insulin secretion studies were performed as previously described [8, 9]. Following a 45 min pre-incubation period at 3.3 mmol/l glucose, groups of 30 islets of comparable size were kept at 37degreesC for 45 min in KRB, 0.5% (wt/wt) albumin, pH 7.4, containing 3.3 mmol/l glucose. At the end of this period, the medium was completely removed and replaced with KRB containing either 3.3, 16.7 or 3.3 mmol/l glucose plus 20 mmol/l arginine, or 3.3 mmol/l glucose plus 100 mumol/l glibenclamide. After an additional 45 min incubation period, the medium was removed. Media (500 mul aliquots from the 10 ml incubation volume) were stored at -20degreesC until insulin concentrations were measured by immunoradiometric assay (Pantec Forniture Biomediche, Turin, Italy).
###end p 21
###begin p 22
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Animals</bold>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 60 71 <span type="species:ncbi:10116">Wistar rats</span>
###xml 312 316 <span type="species:ncbi:10116">rats</span>
Animals Streptozotocin (STZ)-nicotinamide (NA)-treated male Wistar rats (2-3 months old) were administered 210 mg/kg NA i.p. (Sigma, St Louis, MO, USA) dissolved in saline, 15 min before an i.v. injection of 60 mg/kg STZ (Sigma) that had been dissolved in citrate buffer (pH 4.5) immediately before use. Control rats were injected with vehicle alone. STZ-NA-treated animals had stable hyperglycaemia (8.9-10.0 mmol/l) and they were used for the experiments 5 weeks after diabetes was induced. Pancreatic islets were isolated by the collagenase method using the procedure of pancreatic duct cannulation and density gradient purification as described elsewhere [10, 11].
###end p 22
###begin p 23
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Niddm1f</italic>
###xml 396 403 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Niddm1i</italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1473 1475 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 3 7 <span type="species:ncbi:10116">rats</span>
###xml 104 108 <span type="species:ncbi:10116">rats</span>
###xml 266 270 <span type="species:ncbi:10116">rats</span>
###xml 539 543 <span type="species:ncbi:10116">rats</span>
###xml 1052 1056 <span type="species:ncbi:10116">rats</span>
###xml 1086 1090 <span type="species:ncbi:10116">Rats</span>
###xml 1343 1347 <span type="species:ncbi:10116">rats</span>
GK rats were obtained from the Stockholm colony and bred as described [12]. Inbred, normoglycaemic F344 rats were purchased from Charles River Laboratories (Wilmington, MA, USA) and maintained by sister-brother mating. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains F344.GK-Niddm1f (NIDDM1F) and F344.GK-Niddm1i (NIDDM1I). NIDDM1F carries 0.5% of the GK genotype (8 cM), based on genetic distance, on a homozygous F344 genetic background. NIDDM1F rats display hyperglycaemia accompanied by fasting hyperinsulinaemia and increased epididymal fat, implicating insulin resistance. NIDDM1I carries 0.8% of the GK genotype (14 cM), and display hyperglycaemia and insulin secretion defects [13-15]. Backcrossing was designed to introduce mitochondrial DNA and chromosomes X plus Y from F344. The congenic strains were kept constant by sister-brother mating for several generations. To avoid effects of the oestrous cycle and other sex-specific influences, only male rats were included in this study. Rats were maintained at constant temperature and humidity in a 12 h light-dark cycle with free access to standard laboratory chow pellets and water. All experiments were approved by the local Ethics Committees. Isolated pancreatic islets were prepared from rats at 8 weeks of age after a 6 h fast (08:00-14:00 hours), by injection of a collagenase solution via the bile-pancreatic duct [16].
###end p 23
###begin p 24
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of PPARGC1A mRNA expression in pancreatic islets</bold>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 225 228 225 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">260</sub>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 230 233 230 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">280</sub>
###xml 433 441 433 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 531 539 531 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 419 424 <span type="species:ncbi:9606">Human</span>
###xml 429 432 <span type="species:ncbi:10116">rat</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 585 588 <span type="species:ncbi:10116">rat</span>
###xml 770 775 <span type="species:ncbi:9606">human</span>
###xml 790 793 <span type="species:ncbi:10116">rat</span>
Analysis of PPARGC1A mRNA expression in pancreatic islets Total RNA was extracted from human islets, after 3 days in culture, using the RNeasy Protect Mini Kit (Qiagen, Valencia, CA, USA). It was quantified by absorbance at A260/A280 nm (ratio > 1.65) in a Perkin-Elmer spectrophotometer (Waltham, MA, USA) and its integrity was assessed after electrophoresis in 1.0% (wt/wt) agarose gels by ethidium bromide staining. Human and rat PPARGC1A mRNA expression were quantified by RT-PCR [8]. Gene-specific probes and primer pairs for PPARGC1A (Assays-on-demands, human, Hs00173304_m1 and rat, Rn00580241_A1; Applied Biosystems, Foster City, CA, USA) were used. Each sample was run in duplicate and the transcript quantity was normalised to the mRNA level of cyclophilin A (human, 4326316E and rat Rn00574762_A1; Applied Biosystems). For each probe/primer set, a standard curve was generated, which was confirmed to increase linearly with increasing amounts of cDNA.
###end p 24
###begin p 25
###xml 0 72 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Downregulation of PGC-1&#945; in human islets using silencing RNA (siRNA)</bold>
###xml 112 120 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 217 225 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 565 573 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 791 793 787 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 801 803 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1315 1316 1306 1307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 976 982 <span type="species:ncbi:9913">bovine</span>
Downregulation of PGC-1alpha in human islets using silencing RNA (siRNA) In order to test whether inhibition of PPARGC1A expression could directly modulate insulin release, isolated human islets were transfected with PPARGC1A siRNA by using Arrest-In Transfection (Open Biosystem; Celbio, Pero, Italy). This is a polymeric formulation developed and optimised for highly efficient delivery of siRNA into the nucleus of suspension cells in the presence of serum-containing medium. Pre-designed Silencer siRNAs and Silencer non-targeting siRNAs (negative control) for PPARGC1A (Ambion, Austin, TX, USA) were used. Transfection was performed according to the manufacturer's instructions. Briefly, islets obtained from five pancreases were washed 12 times in KRB and exposed for 10 min to free Ca2+- and Mg2+-KRB to allow cell disaggregation. At the end of the incubation period, 400 islets per study point were re-suspended in 800 mul M199 medium (Sigma-Aldrich) added with adult bovine serum. siRNA (80 nmol/l) was diluted in 100 mul M199, while 20 mug Arrest-In solution (Celbio) was dissolved in 100 mul M199 and incubated for 10 min after rapid mixing to allow formation of transfection complexes. Finally, 200 mul of this solution were added into wells containing islets and incubation was allowed for 48 h in a CO2 incubator at 37degreesC. At the end of the incubation period well volume was doubled with M199 culture medium and samples were kept in the incubator for another 48 h, when islets function, viability, transfection efficiency (60% when measured by Polyfectamine tied to a fluorescent probe) and gene expression were evaluated.
###end p 25
###begin p 26
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotyping</bold>
###xml 175 183 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 480 481 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 483 485 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Genotyping Genomic DNA was extracted from pancreatic islets using a Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA). The Gly482Ser (GGT-->AGT) polymorphism of PPARGC1A was genotyped using an allelic discrimination assay performed with an ABI 7900 system (Applied Biosystems), using PCR primers: 5'-CACTTCGGTCATCCCAGTCAA-3' (forward) and 5'-TTATCACTTTCATCTTCGCTGTCATC-3' (reverse), and TaqMan MGB probes: Fam-5'-AGACAAGACCGGTGAA-3' and Vic-5'-CAGACAAGACCAGTGAA-3' [5, 17].
###end p 26
###begin p 27
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNA methylation</bold>
###xml 63 71 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 172 180 172 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1422 1428 1422 1428 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1428 1436 1428 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1516 1524 1516 1524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1586 1587 1586 1587 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1608 1609 1608 1609 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1614 1622 1614 1622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1649 1657 1649 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1702 1703 1702 1703 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1708 1716 1708 1716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1861 1862 1861 1862 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1922 1930 1922 1930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1958 1959 1958 1959 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1986 1987 1986 1987 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1992 2000 1992 2000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 2063 2065 2063 2065 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 2069 2071 2069 2071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 2109 2110 2109 2110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 2132 2140 2132 2140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 2197 2199 2197 2199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 2203 2205 2203 2205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 2270 2271 2270 2271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2280 2281 2280 2281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2331 2332 2329 2330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1428 2339 1428 2337 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><italic>PPARGC1A</italic> mRNA expression in human pancreatic islets is influenced by type 2 diabetes, a <italic>PPARGC1A</italic> Gly482Ser polymorphism and DNA methylation. The influence of <bold>a</bold> type 2 diabetes and <bold>b</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on <italic>PPARGC1A</italic> mRNA expression in human pancreatic islets. <bold>c</bold> The <italic>PPARGC1A</italic> promoter sequence investigated, showing the four DNA methylation target sites; &#8722;772, &#8722;903, &#8722;936 and &#8722;961 and a putative binding-site for HNF-1. <bold>d</bold> The influence of type 2 diabetes on DNA methylation of the <italic>PPARGC1A</italic> promoter. The influence of <bold>e</bold> type 2 diabetes (T2D) and <bold>f</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose. <bold>g</bold> Correlations between <italic>PPARGC1A</italic> mRNA expression and absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose in human pancreatic islets (<italic>r</italic>&#8201;=&#8201;0.38, <italic>p</italic>&#8201;&lt;&#8201;0.05). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p>
###xml 1428 2339 1428 2337 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><italic>PPARGC1A</italic> mRNA expression in human pancreatic islets is influenced by type 2 diabetes, a <italic>PPARGC1A</italic> Gly482Ser polymorphism and DNA methylation. The influence of <bold>a</bold> type 2 diabetes and <bold>b</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on <italic>PPARGC1A</italic> mRNA expression in human pancreatic islets. <bold>c</bold> The <italic>PPARGC1A</italic> promoter sequence investigated, showing the four DNA methylation target sites; &#8722;772, &#8722;903, &#8722;936 and &#8722;961 and a putative binding-site for HNF-1. <bold>d</bold> The influence of type 2 diabetes on DNA methylation of the <italic>PPARGC1A</italic> promoter. The influence of <bold>e</bold> type 2 diabetes (T2D) and <bold>f</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose. <bold>g</bold> Correlations between <italic>PPARGC1A</italic> mRNA expression and absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose in human pancreatic islets (<italic>r</italic>&#8201;=&#8201;0.38, <italic>p</italic>&#8201;&lt;&#8201;0.05). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption>
###xml 2339 2339 2337 2337 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2007_916_Fig1_HTML" id="MO1"/>
###xml 1422 2339 1422 2337 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="28"><italic>PPARGC1A</italic> mRNA expression in human pancreatic islets is influenced by type 2 diabetes, a <italic>PPARGC1A</italic> Gly482Ser polymorphism and DNA methylation. The influence of <bold>a</bold> type 2 diabetes and <bold>b</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on <italic>PPARGC1A</italic> mRNA expression in human pancreatic islets. <bold>c</bold> The <italic>PPARGC1A</italic> promoter sequence investigated, showing the four DNA methylation target sites; &#8722;772, &#8722;903, &#8722;936 and &#8722;961 and a putative binding-site for HNF-1. <bold>d</bold> The influence of type 2 diabetes on DNA methylation of the <italic>PPARGC1A</italic> promoter. The influence of <bold>e</bold> type 2 diabetes (T2D) and <bold>f</bold> the <italic>PPARGC1A</italic> Gly482Ser polymorphism on absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose. <bold>g</bold> Correlations between <italic>PPARGC1A</italic> mRNA expression and absolute insulin release (pmol islet<sup>&#8722;1</sup> min<sup>&#8722;1</sup>) in response to 16.7&#160;mmol/l glucose in human pancreatic islets (<italic>r</italic>&#8201;=&#8201;0.38, <italic>p</italic>&#8201;&lt;&#8201;0.05). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption><graphic position="anchor" xlink:href="125_2007_916_Fig1_HTML" id="MO1"/></fig>
###xml 1456 1461 <span type="species:ncbi:9606">human</span>
###xml 1677 1682 <span type="species:ncbi:9606">human</span>
###xml 2245 2250 <span type="species:ncbi:9606">human</span>
DNA methylation A sequence starting 5,000 bp upstream from the PPARGC1A translation start was used in MethPrimer () to search for regions with CpG sites and PCR designs. A PPARGC1A sequence 986-746 bases upstream from the translation start including four possible DNA-methylation sites and a putative hepatic nuclear factor 1 (HNF-1) binding site, was selected and analysed for DNA methylation (Fig. 1c). Genomic DNA, isolated from pancreatic islets of nine non-diabetic and ten type 2 diabetic multi-organ donors, was treated with bisulphite using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA). Bisulphite-modified DNA was amplified by nested PCR with primers designed using MethPrimer. Primer pair 1: 5'-TAGGGTATTAGGGTTGGAATTTAATG-3' (forward) and 5'-CCCATAACAATAAAAAATACCAACTC-3' (reverse), and primer pair 2 (used for nested PCR): 5'-TATTTTAAGGTAGTTAGGGAGGAAA-3' (forward) and 5'-ATAACAATAAAAAATACCAACTCCC-3' (reverse). The PCR products were then cloned into a vector (TOPO TA Cloning Kit for Sequencing, Invitrogen, Carlsbad, CA, USA) and ten colonies from each donor were purified with a Miniprep kit (Qiagen). These individual clones were sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The number of methylated sites was determined and divided by the total number of methylation sites and then multiplied by 100 to show the percentage of methylation for each donor. Fig. 1PPARGC1A mRNA expression in human pancreatic islets is influenced by type 2 diabetes, a PPARGC1A Gly482Ser polymorphism and DNA methylation. The influence of a type 2 diabetes and b the PPARGC1A Gly482Ser polymorphism on PPARGC1A mRNA expression in human pancreatic islets. c The PPARGC1A promoter sequence investigated, showing the four DNA methylation target sites; -772, -903, -936 and -961 and a putative binding-site for HNF-1. d The influence of type 2 diabetes on DNA methylation of the PPARGC1A promoter. The influence of e type 2 diabetes (T2D) and f the PPARGC1A Gly482Ser polymorphism on absolute insulin release (pmol islet-1 min-1) in response to 16.7 mmol/l glucose. g Correlations between PPARGC1A mRNA expression and absolute insulin release (pmol islet-1 min-1) in response to 16.7 mmol/l glucose in human pancreatic islets (r = 0.38, p < 0.05). Results are expressed as mean +/- SEM. *p < 0.05
###end p 27
###begin p 28
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 88 96 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 158 159 158 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 180 181 180 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 221 229 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 274 275 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 280 288 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 433 434 433 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 494 502 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 530 531 530 531 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 558 559 558 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 564 572 564 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 635 637 635 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 641 643 641 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 681 682 681 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 704 712 704 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 769 771 769 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 775 777 775 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 852 853 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 903 904 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
###xml 817 822 <span type="species:ncbi:9606">human</span>
PPARGC1A mRNA expression in human pancreatic islets is influenced by type 2 diabetes, a PPARGC1A Gly482Ser polymorphism and DNA methylation. The influence of a type 2 diabetes and b the PPARGC1A Gly482Ser polymorphism on PPARGC1A mRNA expression in human pancreatic islets. c The PPARGC1A promoter sequence investigated, showing the four DNA methylation target sites; -772, -903, -936 and -961 and a putative binding-site for HNF-1. d The influence of type 2 diabetes on DNA methylation of the PPARGC1A promoter. The influence of e type 2 diabetes (T2D) and f the PPARGC1A Gly482Ser polymorphism on absolute insulin release (pmol islet-1 min-1) in response to 16.7 mmol/l glucose. g Correlations between PPARGC1A mRNA expression and absolute insulin release (pmol islet-1 min-1) in response to 16.7 mmol/l glucose in human pancreatic islets (r = 0.38, p < 0.05). Results are expressed as mean +/- SEM. *p < 0.05
###end p 28
###begin p 29
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical methods</bold>
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 609 610 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 621 622 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 650 651 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 540 544 <span type="species:ncbi:10116">rats</span>
Statistical methods Differences in PPARGC1A mRNA expression, percentage of DNA methylation and insulin secretion between the different groups studied were analysed using Student's t test or the non-parametric Mann-Whitney test, where appropriate. Correlations were calculated using Pearson correlation coefficients for normally distributed values and Spearman correlation coefficients when normality was rejected. Log values were used in the multivariate regression analysis. Differences in expression between GK, F344, NIDDM1F and NIDDM1I rats were analysed using one-way ANOVA, followed by a Kruskal-Wallis Z test. All p values were two-tailed and p values less than 0.05 were considered significant. Statistical calculations were performed by NCSS software (NCSS Statistical Software, Kaysville, UT, USA).
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 23 31 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 161 162 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 177 178 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 223 231 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 303 311 299 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 409 410 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 444 445 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 453 454 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 472 473 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 513 521 505 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 597 598 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 630 631 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
The mRNA expression of PPARGC1A was markedly reduced in pancreatic islets from type 2 diabetic compared with non-diabetic donors (1.06 +/- 0.63 vs 15.0 +/- 3.0; p < 0.005; Fig. 1a). Intriguingly, non-diabetic carriers of a PPARGC1A 482Ser allele, Gly/Ser or Ser/Ser genotype carriers had markedly lower PPARGC1A mRNA expression compared with carriers of the Gly/Gly genotype [Gly/Ser + Ser/Ser 3.43 +/- 0.94 (n = 17) vs Gly/Gly 26.53 +/- 4.42 (n = 17); p < 0.00005] (Fig. 1b). However, there was no difference in PPARGC1A mRNA expression between non-diabetic carriers of the Gly/Ser (3.9 +/- 4.0; n = 11) or Ser/Ser (2.7 +/- 5.5; n = 6) genotypes. This demonstrates that the effect of the genotype on gene expression is seen already in the pre-diabetic state.
###end p 31
###begin p 32
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 342 350 342 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 181 186 <span type="species:ncbi:9606">human</span>
The diabetic donors were significantly older and had higher BMI than control donors (Table 1). We therefore tested whether these factors might also relate to PPARGC1A expression in human islets using a multivariate regression analysis including age, BMI and disease status as covariates. Only disease status was significantly associated with PPARGC1A expression in this analysis (r = 1.04; p = 0.0065).
###end p 32
###begin p 33
###xml 87 95 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 401 409 401 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 603 611 603 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 704 705 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 719 720 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 759 767 755 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 857 858 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 959 967 955 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 985 986 981 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 996 997 992 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 660 665 <span type="species:ncbi:9606">human</span>
We next evaluated whether epigenetic phenomena such as DNA methylation would influence PPARGC1A expression in islets. Cytosine residues occurring in CG dinucleotides are targets for DNA methylation, and gene expression is usually reduced when DNA is methylated at the promoter. We used bisulphite sequencing to assess DNA methylation of four methylation target sites, -772, -903, -936 and -961 in the PPARGC1A promoter in pancreatic islets from the type 2 diabetic and non-diabetic human multi-organ donors (Fig. 1c). Interestingly, there was an approximately twofold increase in DNA methylation of the PPARGC1A promoter of diabetic compared with non-diabetic human islets (10.5 +/- 2.7 vs 4.7 +/- 0.9%; p < 0.04; Fig. 1d). Also in this subset of donors, the PPARGC1A mRNA expression was significantly reduced in diabetic compared with non-diabetic islets (p = 0.002). There was a trend towards an inverse correlation between the level of DNA methylation and PPARGC1A mRNA expression (r = -0.48; p = 0.08, after adjustment for disease status).
###end p 33
###begin p 34
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 33 35 33 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 170 171 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 227 235 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 376 377 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 391 392 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 434 442 426 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 504 505 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 514 515 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 529 530 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 548 556 540 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 716 717 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 818 819 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 903 904 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Insulin release (pmol islet-1 min-1) in response to 16.7 mmol/l glucose was reduced in type 2 diabetic compared with non-diabetic islets (0.32 +/- 0.04 vs 0.55 +/- 0.05; p < 0.01) as well as in non-diabetic islets carrying the PPARGC1A 482Ser allele (Gly/Ser + Ser/Ser) compared with carriers of the Gly/Gly genotype (Gly/Ser + Ser/Ser 0.43 +/- 0.06 vs Gly/Gly 0.64 +/- 0.07; p < 0.05; Fig. 1e-f). In addition, the mRNA expression of PPARGC1A correlated positively with glucose-mediated insulin release (r = 0.38; p < 0.05; Fig. 1g). Moreover, the PPARGC1A Gly482Ser polymorphism did not significantly affect basal insulin secretion at 3.3 mmol/l glucose (Gly/Ser + Ser/Ser, 0.23 +/- 0.01 vs Gly/Gly, 0.29 +/- 0.02; p = 0.13), or insulin response to arginine (Gly/Ser + Ser/Ser 0.48 +/- 0.05 vs Gly/Gly 0.53 +/- 0.08; p = 0.77) or glibenclamide (Gly/Ser + Ser/Ser 0.59 +/- 0.1 vs Gly/Gly 0.56 +/- 0.09; p = 0.98).
###end p 34
###begin p 35
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 126 134 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 310 318 306 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 326 327 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 365 366 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 454 462 450 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 464 465 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 506 507 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 623 624 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 893 901 885 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 988 989 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 999 1005 985 991 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1050 1058 1036 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1107 1108 1093 1094 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1108 1116 1094 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1118 1119 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1129 1130 1115 1116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1140 1141 1126 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1151 1152 1137 1138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1273 1274 1259 1260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1301 1309 1287 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1391 1392 1377 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1439 1440 1423 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1005 1447 991 1431 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Transfection of human pancreatic islets with <italic>PPARGC1A</italic> siRNA is associated with reduced mRNA levels of <bold>a</bold><italic>PPARGC1A</italic> (<italic>n</italic>&#8201;=&#8201;3) and <bold>b</bold> insulin (<italic>n</italic>&#8201;=&#8201;5) and <bold>c</bold> concomitant reduction of the insulin stimulation index (ISI), i.e. incremental fold change above basal insulin release. <bold>d</bold> Conversely, inhibition of <italic>PPARGC1A</italic> expression in human pancreatic islets has no effect on glucagon mRNA expression (<italic>n</italic>&#8201;=&#8201;5). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p>
###xml 1005 1447 991 1431 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Transfection of human pancreatic islets with <italic>PPARGC1A</italic> siRNA is associated with reduced mRNA levels of <bold>a</bold><italic>PPARGC1A</italic> (<italic>n</italic>&#8201;=&#8201;3) and <bold>b</bold> insulin (<italic>n</italic>&#8201;=&#8201;5) and <bold>c</bold> concomitant reduction of the insulin stimulation index (ISI), i.e. incremental fold change above basal insulin release. <bold>d</bold> Conversely, inhibition of <italic>PPARGC1A</italic> expression in human pancreatic islets has no effect on glucagon mRNA expression (<italic>n</italic>&#8201;=&#8201;5). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption>
###xml 1447 1447 1431 1431 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2007_916_Fig2_HTML" id="MO2"/>
###xml 999 1447 985 1431 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="36">Transfection of human pancreatic islets with <italic>PPARGC1A</italic> siRNA is associated with reduced mRNA levels of <bold>a</bold><italic>PPARGC1A</italic> (<italic>n</italic>&#8201;=&#8201;3) and <bold>b</bold> insulin (<italic>n</italic>&#8201;=&#8201;5) and <bold>c</bold> concomitant reduction of the insulin stimulation index (ISI), i.e. incremental fold change above basal insulin release. <bold>d</bold> Conversely, inhibition of <italic>PPARGC1A</italic> expression in human pancreatic islets has no effect on glucagon mRNA expression (<italic>n</italic>&#8201;=&#8201;5). Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption><graphic position="anchor" xlink:href="125_2007_916_Fig2_HTML" id="MO2"/></fig>
###xml 280 285 <span type="species:ncbi:9606">human</span>
###xml 1021 1026 <span type="species:ncbi:9606">human</span>
###xml 1324 1329 <span type="species:ncbi:9606">human</span>
Having seen the relationship between PPARGC1A expression and insulin secretion, we set out to determine whether modulation of PPARGC1A expression would influence insulin secretion. This was achieved by studying insulin secretion after experimental downregulation of PGC-1alpha in human islets transfected with PPARGC1A siRNA (n = 3-5 experiments). As shown in Fig. 2, transfection with siRNA was associated with a 45% reduction in the mRNA expression of PPARGC1A (p = 0.01), 32% reduction in insulin mRNA (p = 0.05) and 41% reduction of the insulin stimulation index (i.e. incremental folds above baseline insulin release; p = 0.01). Notably, no significant change was seen in glucagon mRNA expression, suggesting that the effect was primarily due to a downregulation of PGC-1alpha in beta cells. As a negative control, transfection with scrambled siRNA was not associated with any changes in PPARGC1A (1.26 +/- 0.25), insulin (1.29 +/- 0.16) or glucagon (0.99 +/- 0.15) mRNA expression (p > 0.05). Fig. 2Transfection of human pancreatic islets with PPARGC1A siRNA is associated with reduced mRNA levels of aPPARGC1A (n = 3) and b insulin (n = 5) and c concomitant reduction of the insulin stimulation index (ISI), i.e. incremental fold change above basal insulin release. d Conversely, inhibition of PPARGC1A expression in human pancreatic islets has no effect on glucagon mRNA expression (n = 5). Results are expressed as mean +/- SEM. *p < 0.05
###end p 35
###begin p 36
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 102 103 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 103 111 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 124 125 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 146 147 146 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 268 269 268 269 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 296 304 296 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 434 435 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
Transfection of human pancreatic islets with PPARGC1A siRNA is associated with reduced mRNA levels of aPPARGC1A (n = 3) and b insulin (n = 5) and c concomitant reduction of the insulin stimulation index (ISI), i.e. incremental fold change above basal insulin release. d Conversely, inhibition of PPARGC1A expression in human pancreatic islets has no effect on glucagon mRNA expression (n = 5). Results are expressed as mean +/- SEM. *p < 0.05
###end p 36
###begin p 37
###xml 23 31 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 177 179 173 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 180 182 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 233 234 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 302 310 298 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 378 386 374 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 522 523 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 538 539 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 553 561 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 751 752 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 827 828 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 858 866 846 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 944 945 932 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 949 955 937 943 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 955 963 943 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1009 1010 997 998 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1071 1072 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1100 1101 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1108 1110 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1112 1114 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1120 1128 1108 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1338 1339 1326 1327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1339 1347 1327 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1512 1513 1500 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1582 1584 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1616 1617 1604 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1845 1846 1833 1834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2067 2068 2055 2056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2153 2155 2141 2143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 2156 2158 2144 2146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 2201 2202 2187 2188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 955 2209 943 2195 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><italic>PPARGC1A</italic> mRNA expression in rodent pancreatic islets. <bold>a</bold> Male Wistar rats (2&#8211;3&#160;months old) were treated with STZ&#8211;NA (<italic>n</italic>&#8201;=&#8201;5) or vehicles (control; <italic>n</italic>&#8201;=&#8201;5) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and <italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets isolated from STZ&#8211;NA-treated animals showing a stable hyperglycaemia (8.9&#8211;10.0&#160;mmol glucose/l) and controls. <bold>b</bold><italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets prepared from rats at 8&#160;weeks of age after a 6&#160;h fast. GK rats (<italic>n</italic>&#8201;=&#8201;6) were obtained from the Stockholm colony and bred as described [<xref ref-type="bibr" rid="CR12">12</xref>]. Inbred, normoglycaemic F344 (<italic>n</italic>&#8201;=&#8201;6) were purchased from Charles River Laboratories. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains NIDDM1F and NIDDM1I. NIDDM1F rats (<italic>n</italic>&#8201;=&#8201;6) carry 0.5% of the GK genotype, based on genetic distance, on a homozygous F344 genetic background (8&#160;cM) and display hyperglycaemia accompanied by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I (<italic>n</italic>&#8201;=&#8201;6) carries 0.8% of the GK genotype (14&#160;cM) and display insulin secretion defects [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p>
###xml 955 2209 943 2195 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><italic>PPARGC1A</italic> mRNA expression in rodent pancreatic islets. <bold>a</bold> Male Wistar rats (2&#8211;3&#160;months old) were treated with STZ&#8211;NA (<italic>n</italic>&#8201;=&#8201;5) or vehicles (control; <italic>n</italic>&#8201;=&#8201;5) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and <italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets isolated from STZ&#8211;NA-treated animals showing a stable hyperglycaemia (8.9&#8211;10.0&#160;mmol glucose/l) and controls. <bold>b</bold><italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets prepared from rats at 8&#160;weeks of age after a 6&#160;h fast. GK rats (<italic>n</italic>&#8201;=&#8201;6) were obtained from the Stockholm colony and bred as described [<xref ref-type="bibr" rid="CR12">12</xref>]. Inbred, normoglycaemic F344 (<italic>n</italic>&#8201;=&#8201;6) were purchased from Charles River Laboratories. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains NIDDM1F and NIDDM1I. NIDDM1F rats (<italic>n</italic>&#8201;=&#8201;6) carry 0.5% of the GK genotype, based on genetic distance, on a homozygous F344 genetic background (8&#160;cM) and display hyperglycaemia accompanied by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I (<italic>n</italic>&#8201;=&#8201;6) carries 0.8% of the GK genotype (14&#160;cM) and display insulin secretion defects [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption>
###xml 2209 2209 2195 2195 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2007_916_Fig3_HTML" id="MO3"/>
###xml 949 2209 937 2195 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="38"><italic>PPARGC1A</italic> mRNA expression in rodent pancreatic islets. <bold>a</bold> Male Wistar rats (2&#8211;3&#160;months old) were treated with STZ&#8211;NA (<italic>n</italic>&#8201;=&#8201;5) or vehicles (control; <italic>n</italic>&#8201;=&#8201;5) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and <italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets isolated from STZ&#8211;NA-treated animals showing a stable hyperglycaemia (8.9&#8211;10.0&#160;mmol glucose/l) and controls. <bold>b</bold><italic>PPARGC1A</italic> mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets prepared from rats at 8&#160;weeks of age after a 6&#160;h fast. GK rats (<italic>n</italic>&#8201;=&#8201;6) were obtained from the Stockholm colony and bred as described [<xref ref-type="bibr" rid="CR12">12</xref>]. Inbred, normoglycaemic F344 (<italic>n</italic>&#8201;=&#8201;6) were purchased from Charles River Laboratories. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains NIDDM1F and NIDDM1I. NIDDM1F rats (<italic>n</italic>&#8201;=&#8201;6) carry 0.5% of the GK genotype, based on genetic distance, on a homozygous F344 genetic background (8&#160;cM) and display hyperglycaemia accompanied by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I (<italic>n</italic>&#8201;=&#8201;6) carries 0.8% of the GK genotype (14&#160;cM) and display insulin secretion defects [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Results are expressed as mean&#8201;&#177;&#8201;SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05</p></caption><graphic position="anchor" xlink:href="125_2007_916_Fig3_HTML" id="MO3"/></fig>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 188 191 <span type="species:ncbi:10116">rat</span>
###xml 219 223 <span type="species:ncbi:10116">rats</span>
###xml 366 369 <span type="species:ncbi:10116">rat</span>
###xml 446 457 <span type="species:ncbi:10116">Wistar rats</span>
###xml 771 774 <span type="species:ncbi:10116">rat</span>
###xml 926 929 <span type="species:ncbi:10116">rat</span>
###xml 1016 1027 <span type="species:ncbi:10116">Wistar rats</span>
###xml 1462 1466 <span type="species:ncbi:10116">rats</span>
###xml 1506 1510 <span type="species:ncbi:10116">rats</span>
###xml 1718 1722 <span type="species:ncbi:10116">rats</span>
###xml 1839 1843 <span type="species:ncbi:10116">rats</span>
The finding of reduced PPARGC1A expression in human diabetic islets was somewhat surprising given an earlier report of increased PGC-1alpha levels in islets from diabetic mice (ob/ob) and rat (ZDF and pancreatectomised rats) models [7]. To further explore species-specific differences we also measured PPARGC1A mRNA expression in pancreatic islets from two diabetic rat models. PPARGC1A expression was reduced in islets from STZ-NA diabetic male Wistar rats compared with control animals (3.08 +/- 1.07 vs 10.26 +/- 1.12; p < 0.009; Fig. 3a). Moreover, PPARGC1A expression was reduced in islets from the congenic NIDDM1I strain, which has insulin secretion defects, compared with the insulin-resistant NIDDM1F strain (7.18 +/- 1.79 vs 11.30 +/- 1.79; p < 0.02) of the GK rat, an animal model of polygenic type 2 diabetes (Fig. 3b). However, no difference in PPARGC1A expression was found when comparing islets from F344 or GK rat strains (Fig. 3b). Fig. 3PPARGC1A mRNA expression in rodent pancreatic islets. a Male Wistar rats (2-3 months old) were treated with STZ-NA (n = 5) or vehicles (control; n = 5) [10, 11] and PPARGC1A mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets isolated from STZ-NA-treated animals showing a stable hyperglycaemia (8.9-10.0 mmol glucose/l) and controls. bPPARGC1A mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets prepared from rats at 8 weeks of age after a 6 h fast. GK rats (n = 6) were obtained from the Stockholm colony and bred as described [12]. Inbred, normoglycaemic F344 (n = 6) were purchased from Charles River Laboratories. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains NIDDM1F and NIDDM1I. NIDDM1F rats (n = 6) carry 0.5% of the GK genotype, based on genetic distance, on a homozygous F344 genetic background (8 cM) and display hyperglycaemia accompanied by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I (n = 6) carries 0.8% of the GK genotype (14 cM) and display insulin secretion defects [13-15]. Results are expressed as mean +/- SEM. *p < 0.05
###end p 37
###begin p 38
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 54 55 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 145 146 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 165 173 165 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 383 384 383 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 384 392 384 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 890 891 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1112 1113 1112 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1201 1203 1201 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1246 1247 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 61 72 <span type="species:ncbi:10116">Wistar rats</span>
###xml 507 511 <span type="species:ncbi:10116">rats</span>
###xml 551 555 <span type="species:ncbi:10116">rats</span>
###xml 763 767 <span type="species:ncbi:10116">rats</span>
###xml 884 888 <span type="species:ncbi:10116">rats</span>
PPARGC1A mRNA expression in rodent pancreatic islets. a Male Wistar rats (2-3 months old) were treated with STZ-NA (n = 5) or vehicles (control; n = 5) [10, 11] and PPARGC1A mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets isolated from STZ-NA-treated animals showing a stable hyperglycaemia (8.9-10.0 mmol glucose/l) and controls. bPPARGC1A mRNA expression together with the internal standard cyclophilin A was analysed in pancreatic islets prepared from rats at 8 weeks of age after a 6 h fast. GK rats (n = 6) were obtained from the Stockholm colony and bred as described [12]. Inbred, normoglycaemic F344 (n = 6) were purchased from Charles River Laboratories. Transfer of GK alleles onto the genome of F344 rats by repeated backcrossing (ten generations) established the homozygous congenic strains NIDDM1F and NIDDM1I. NIDDM1F rats (n = 6) carry 0.5% of the GK genotype, based on genetic distance, on a homozygous F344 genetic background (8 cM) and display hyperglycaemia accompanied by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I (n = 6) carries 0.8% of the GK genotype (14 cM) and display insulin secretion defects [13-15]. Results are expressed as mean +/- SEM. *p < 0.05
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 197 205 197 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 419 427 419 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 508 516 508 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 454 459 <span type="species:ncbi:9606">human</span>
###xml 531 536 <span type="species:ncbi:9606">human</span>
###xml 819 824 <span type="species:ncbi:9606">human</span>
The key results from the present study were that PPARGC1A mRNA expression and insulin secretion were reduced in pancreatic islets of patients with type 2 diabetes and in non-diabetic carriers of a PPARGC1A 482Ser allele, a genotype previously associated with the disease. Moreover, we demonstrate that epigenetic mechanisms are likely to be operative in the pathogenesis of type 2 diabetes since DNA methylation of the PPARGC1A promoter was increased in human diabetic islets. Experimental downregulation of PPARGC1A expression in human islets by siRNA resulted in decreased insulin secretion thereby demonstrating a causal link between PGC-1alpha levels and insulin secretion. Based on these observations we propose a model where combinations of genetic and epigenetic factors can influence the level of PGC-1alpha in human islets and subsequently glucose-stimulated insulin secretion.
###end p 40
###begin p 41
###xml 272 280 268 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 393 394 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 396 398 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 660 668 652 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
The transcriptional coactivator PGC-1alpha is an important factor regulating the expression of genes for oxidative phosphorylation in a number of tissues including skeletal muscle, liver and adipose tissue. We and others have previously demonstrated reduced expression of PPARGC1A and a set of genes involved in oxidative phosphorylation in skeletal muscle from patients with type 2 diabetes [2, 18]. However, the level and role of PGC-1alpha in pancreatic islets of patients with type 2 diabetes remained to be determined. The present results indicate that the situation in human islets mirrors the situation in skeletal muscle, since the expression level of PPARGC1A was reduced in human type 2 diabetic islets, thus providing evidence for a common defect that may simultaneously contribute to peripheral insulin resistance and impairment of beta cell function.
###end p 41
###begin p 42
###xml 131 133 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 134 136 130 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 180 181 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 536 544 524 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 560 568 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1174 1182 1158 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 1341 1349 1325 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 38 44 <span type="species:ncbi:9606">humans</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10116">rats</span>
###xml 174 178 <span type="species:ncbi:10116">rats</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
###xml 674 685 <span type="species:ncbi:10116">Wistar rats</span>
###xml 740 743 <span type="species:ncbi:10116">rat</span>
###xml 1063 1066 <span type="species:ncbi:10116">rat</span>
###xml 1160 1165 <span type="species:ncbi:9606">human</span>
###xml 1245 1248 <span type="species:ncbi:10116">rat</span>
###xml 1405 1410 <span type="species:ncbi:9606">human</span>
In contrast to the present results in humans, elevated PGC-1alpha levels have been reported in islets from diabetic rodent models, ob/ob mice, ZDF rats and pancreatectomised rats [7]. In these rodent models, the increase in PGC-1alpha was associated with suppressed beta cell metabolism and insulin release. This could reflect true species differences, but also differences in experimental conditions. To address this issue, we determined: (1) the effect of inhibiting PGC-1alpha production by transfecting human pancreatic islets with PPARGC1A siRNA; and (2) PPARGC1A expression in pancreatic islets of different rodent models with experimental diabetes, i.e. STZ-diabetic Wistar rats and congenic strains from the type 2 diabetes-like GK rat. Silencing PGC-1alpha production was associated with concomitant reduction of insulin mRNA expression and insulin release in response to glucose. This effect appears to be highly specific for insulin regulation as it had no effect whatsoever on glucagon mRNA expression. The congenic strains have been bred from the GK rat based upon low insulin secretion or insulin resistance. In line with the results observed in human islets, PPARGC1A expression was reduced in islets from diabetic animals and in rat strains with suppressed insulin secretion. Collectively, these data support the notion that PPARGC1A expression is reduced in animal models of diabetes and human diabetes, and associated with impaired insulin secretion.
###end p 42
###begin p 43
###xml 326 334 326 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 492 500 492 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 585 593 585 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 642 650 642 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 520 525 <span type="species:ncbi:9606">human</span>
###xml 696 701 <span type="species:ncbi:9606">human</span>
The risk of developing type 2 diabetes increases with high-fat/high-energy diets, reduced physical activity and age. However, not all individuals respond to the environment in the same way. This variation in response to environmental factors has partially been ascribed to genetic factors. The common Gly482Ser variant in the PPARGC1A gene is a plausible candidate for such a genetic factor [3, 4]. We have previously shown that this polymorphism is associated with an age-related decline in PPARGC1A gene expression in human skeletal muscle [5]. The present study shows that the same PPARGC1A risk allele, 482Ser, is associated with reduced PPARGC1A expression and impaired insulin secretion in human islets. Thus, our results provide the ground for a common genetic predisposition towards type 2 diabetes contributing to both impaired insulin action and secretion.
###end p 43
###begin p 44
###xml 8 16 8 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 179 187 179 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 566 574 566 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 802 807 <span type="species:ncbi:9606">human</span>
Reduced PPARGC1A expression may not simply reflect an effect of the polymorphism per se but could also occur through epigenetic phenomena such as increased DNA methylation of the PPARGC1A promoter. Cytosine residues occurring in CG dinucleotides are targets for DNA methylation, and gene expression is usually reduced when DNA methylation takes place at a promoter. Epigenetic changes are well known to influence gene expression of suppressor genes and oncogenes in cancer cells and contribute to tumour growth [19]. Increased DNA methylation of the promoter of the PPARGC1A gene in type 2 diabetic human islets may contribute to beta cell dysfunction by similar mechanisms. To our knowledge, this is the first study to demonstrate that DNA methylation may play a role in regulating gene expression in human diabetic islets.
###end p 44
###begin p 45
###xml 294 302 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 395 403 391 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 572 580 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 663 671 659 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 788 796 784 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 440 445 <span type="species:ncbi:9606">human</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 846 851 <span type="species:ncbi:9606">human</span>
Our data suggest that PGC-1alpha can modulate glucose-mediated insulin secretion in human islets, most likely via an effect on ATP production as indicated by normal insulin release in response to arginine and glibenclamide, which stimulate insulin downstream of ATP. In support of such a role, PPARGC1A mRNA expression correlated with glucose-stimulated insulin release. Moreover, inhibition of PPARGC1A expression by siRNA transfection in human islets was associated with a decline in insulin mRNA and insulin release. Similarly, in human type 2 diabetic islets, reduced PPARGC1A mRNA levels were associated with impaired glucose-mediated insulin secretion. The PPARGC1A Gly482Ser polymorphism, which previously has been associated with type 2 diabetes, was also associated with reduced PPARGC1A expression and impaired insulin secretion in the human islets.
###end p 45
###begin p 46
###xml 195 203 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 265 266 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 359 367 351 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 556 564 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:9606">human</span>
One caveat of this study could be that we did not measure the protein level of PGC-1alpha in human islets. However, we have previously demonstrated a significant positive correlation between the PPARGC1A mRNA and PGC-1alpha protein levels in human skeletal muscle [5] and we therefore assume that this might also be the case in human islets. The reduction in PPARGC1A expression in non-diabetic carriers of a 482Ser allele was strong and factors other than haploinsufficiency may therefore explain this reduction. Moreover, whether the genotype influences PPARGC1A expression in diabetic islets would be of interest; however, the present study lacks statistical power to perform this analysis. These relationships should be addressed in future ad hoc studies.
###end p 46
###begin p 47
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 224 232 224 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
In conclusion, we have shown that PPARGC1A mRNA expression is reduced in islets from patients with type 2 diabetes and it is influenced by both genetic (Gly482Ser) and epigenetic (DNA methylation) factors. This reduction in PPARGC1A expression correlated with impaired glucose-stimulated insulin secretion, which is known to require ATP. Thereby, the present study provides two novel insights into the molecular mechanisms of islet dysfunction in type 2 diabetes; first that a master transcription regulator of oxidative phosphorylation, PGC-1alpha, may be involved and second, that epigenetic factors like DNA methylation should be considered when searching for the genetic causes of type 2 diabetes.
###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
This investigation was supported by Linne Grant B31 5631/2006 and Grant 522-2006-6480 from the Swedish Research Council. Additional grants were received from: Region Skane; Malmo University Hospital; Swegene; The Diabetes Programme at Lund University; Novo Nordisk; Crafoord; Hedlund; Bergvall; Wiberg; Pahlsson; Hains; and Lundberg.
###end p 49
###begin p 50
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 50
###begin p 51
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Metabolic control through the PGC-1 family of transcription coactivators
###end article-title 53
###begin article-title 54
###xml 100 105 <span type="species:ncbi:9606">human</span>
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
###end article-title 54
###begin article-title 55
Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus
###end article-title 55
###begin article-title 56
###xml 42 50 42 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARGC1A</italic>
Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes
###end article-title 56
###begin article-title 57
Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins
###end article-title 57
###begin article-title 58
Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes
###end article-title 58
###begin article-title 59
Suppression of beta cell energy metabolism and insulin release by PGC-1alpha
###end article-title 59
###begin article-title 60
###xml 57 62 <span type="species:ncbi:9606">human</span>
Functional and molecular defects of pancreatic islets in human type 2 diabetes
###end article-title 60
###begin article-title 61
###xml 16 21 <span type="species:ncbi:9606">human</span>
Lipotoxicity in human pancreatic islets and the protective effect of metformin
###end article-title 61
###begin article-title 62
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Metabolic and functional studies on isolated islets in a new rat model of type 2 diabetes
###end article-title 62
###begin article-title 63
###xml 56 60 <span type="species:ncbi:10116">rats</span>
Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide
###end article-title 63
###begin article-title 64
###xml 70 73 <span type="species:ncbi:10116">rat</span>
Genetic analysis of non-insulin dependent diabetes mellitus in the GK rat
###end article-title 64
###begin article-title 65
###xml 86 90 <span type="species:ncbi:10116">rats</span>
Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats
###end article-title 65
###begin article-title 66
###xml 82 86 <span type="species:ncbi:10116">rats</span>
Pathophysiological and genetic characterization of the major diabetes locus in GK rats
###end article-title 66
###begin article-title 67
###xml 148 152 <span type="species:ncbi:10116">rats</span>
Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddm1i within the major diabetes locus in GK rats
###end article-title 67
###begin article-title 68
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
An improved method for isolation of mouse pancreatic islets
###end article-title 68
###begin article-title 69
A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians
###end article-title 69
###begin article-title 70
###xml 58 64 <span type="species:ncbi:9606">humans</span>
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1
###end article-title 70
###begin article-title 71
New therapeutic targets in cancer: the epigenetic connection
###end article-title 71
###begin title 72
Abbreviations
###end title 72
###begin p 73
hepatic nuclear factor 1
###end p 73
###begin p 74
nicotinamide
###end p 74
###begin p 75
peroxisome proliferator activated receptor gamma coactivator-1 alpha
###end p 75
###begin p 76
silencing RNA
###end p 76
###begin p 77
streptozotocin
###end p 77
###begin p 78
*L. Groop and S. Del Prato contributed equally to this study.
###end p 78

